Cabot Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Cabot Wealth Management's VRTX Position: Q2 2026 in Review
Cabot Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 104% in Q2 2026, buying an estimated $429K and bringing the position to 1,899 shares worth $943K. The position accounts for 0.1% of the portfolio, ranked #94.
Cabot Wealth Management first reported a position in VRTX in Q3 2025 and has held it in 4 quarters since. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Cabot Wealth Management held 1,899 shares of Vertex Pharmaceuticals worth $943K as of Q2 2026.
- Cabot Wealth Management bought 969 Vertex Pharmaceuticals shares in Q2 2026, an estimated $429K.
- Vertex Pharmaceuticals made up 0.1% of Cabot Wealth Management's portfolio in Q2 2026, its #94 holding.
- Cabot Wealth Management first reported a position in Vertex Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
- 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Cabot Wealth Management's 13F filing for Q2 2026, filed 31 Jul 2026.